Open Access
Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

Time dependent ethnic convergence in colorectal cancer survival in hawaii

  • Ian S Pagano1Email author,
  • Shane Y Morita2,
  • Sanjaya Dhakal1,
  • Scott A Hundahl3 and
  • Gertraud Maskarinec1
BMC Cancer20033:5

DOI: 10.1186/1471-2407-3-5

Received: 8 November 2002

Accepted: 25 February 2003

Published: 25 February 2003

Abstract

Background

Although colorectal cancer death rates have been declining, this trend is not consistent across all ethnic groups. Biological, environmental, behavioral and socioeconomic explanations exist, but the reason for this discrepancy remains inconclusive. We examined the hypothesis that improved cancer screening across all ethnic groups will reduce ethnic differences in colorectal cancer survival.

Methods

Through the Hawaii Tumor Registry 16,424 patients diagnosed with colorectal cancer were identified during the years 1960–2000. Cox regression analyses were performed for each of three cohorts stratified by ethnicity (Caucasian, Japanese, Hawaiian, Filipino, and Chinese). The models included stage of diagnosis, year of diagnosis, age, and sex as predictors of survival.

Results

Mortality rates improved significantly for all ethnic groups. Moreover, with the exception of Hawaiians, rates for all ethnic groups converged over time. Persistently lower survival for Hawaiians appeared linked with more cancer treatment.

Conclusion

Ethnic disparities in colorectal cancer mortality rates appear primarily the result of differential utilization of health care. If modern screening procedures can be provided equally to all ethnic groups, ethnic outcome differences can be virtually eliminated.

Background

After lung, prostate, and breast cancer, colorectal cancer ranks as a leading source of cancer mortality.[1] Nationally, although death rates have been declining since the mid-1980s, this trend is not consistent across all ethnic groups.[2] Specifically, in the past 10 years the death rate for Caucasians has been decreasing at nearly twice the rate as that for African Americans, and for Native Americans the rate has actually been increasing.[3, 4] Among Asian ethnic groups, Chinese and Filipinos suffer a higher death rate than do the Japanese.[5] These ethnic disparities appear largely driven by differential stage distribution (e.g., more advanced stage cases at presentation). Underutilization of cancer screening appears a key factor.[6] However, studies have found that even after controlling for stage at diagnosis, significant ethnic differences remain.[7]

How can one explain cancer survival differences that persist after adjustment for stage? Biological theories suggest that members of certain ethnic groups are genetically predisposed to more aggressive forms of the disease, differ in host-tumor interactions, or are more likely to have contributing comorbid conditions. Wudel et al. (2002) recently reported that colorectal cancer survival differences between Caucasians and African Americans could not be explained by measurable differences in treatment.[8] Neuhausen has proposed a multi-factorial biology-utilization model.[9] Environmental theories propose that behavioral or socioeconomic factors leading to differential utilization of medical care are responsible. Varying utilization of, as well as access to health care has been reported as an explanation. [1012] Schrijvers et al. (1997) have described a relation between socioeconomic status and comorbidity.[13] Evidence of interaction between age and socioeconomic status has also been reported.[14]

Hawaii's diverse ethnic composition combined with its long-standing statewide cancer registry, the Hawaii Tumor Registry (HTR), offer an ideal setting for examining ethnic differences in cancer survival. Previous research has documented significant survival disparities among the major ethnic groups (Caucasian, Japanese, Hawaiian, Filipino, and Chinese) in the state. In 1978, Nomura et al. found that Japanese patients had a nearly one-third higher survival rate than Caucasians.[15] Hirohata et al. (1977) described better survival rates among Japanese and Caucasians than among Filipinos and Hawaiians, even after adjusting for age, gender, and extent of disease at diagnosis.[16] Wegner et al. (1982) analyzed HTR data from 1960–1974 and found the same pattern of differences, which also could not be explained by any of the available covariates.[17]

The goal of the present study is to examine trends in recent survival rates. The HTR data that was incorporated in the Wegner (1982) study is still available as is more recent data up to the year 2000, allowing for an examination of survival patterns over time. Improved survival rates for cancer patients were observed by Hinds et al. (1983) during the years 1960–1974.[18] More recently, Maskarinec et al. (1999) have described improved breast cancer survival among all ethnic groups for 1970–1990.[19] Also, for the years 1995–1998 it was found that all ethnic disparities in breast cancer survival were eliminated once TNM Stage had been controlled.[20] These findings largely fail to support purely biologic explanations of disparate colorectal cancer survival. Differential utilization of health care or access to health care appears more important.

In Hawaii, the passage of time has brought general improvements in medical care and also narrowed disparities in access to medical care. Utilization of screening procedures continues to vary among ethnic groups, however. At the onset of this study, we hypothesized that, over the past 30 years, improved cancer screening and treatment, as well as better access to medical care across all ethnic groups has both improved survival rates and reduced ethnic differences in colorectal cancer survival. We further predicted that stage at diagnosis, age, and gender could explain most remaining survival differences, although we questioned the role of other factors such as treatment utilization and co-morbid disease.

Methods

Population and Sample

The population of Hawaii resides on seven islands with 80% on the island of Oahu and is estimated at 1.2 million with approximately 580,000 women. [21] Close to 13% of residents are 65 years and older and 40% are 40 years and older. The majority of the population is of Asian and Pacific Islander descent: 24.1% of the population in 1990 were Caucasian, 20.4% Japanese, 18.8% Native Hawaiian, 11.4% Filipino, 4.7% Chinese, and the rest other ethnic groups. However, over the period of this study, differences in age distribution within various ethnic groups in Hawaii have driven some differences in the actual proportions of individuals with cancer.

All data were ascertained through the Hawaii Tumor Registry (HTR), which provides population-based coverage of all newly diagnosed cancer cases and subsequent follow-up status for residents of Hawaii. The HTR was established in 1960 and it became part of the Surveillance, Epidemiology, and End Results (SEER) program in 1973. Quality control reviews have shown that case-ascertainment through HTR is virtually complete. Over 99% of cancer cases reported to the registry are histologically confirmed[22] and less than 2% of cases are identified through death certificates only. Whenever possible, the HTR follows cases until death through regular linkages with the Hawaii Department of Health's death records, hospital-based registries, and additional sources of mortality information. In accordance with SEER rules, less than 5% of cases are lost to follow-up. The ethnicity classification in the HTR is based on self-reports by patients. Information on the first course of treatment (surgery, chemotherapy, radiation, and hormone therapy) is also collected.[23]

From the HTR, all patients diagnosed with colorectal cancer (ICD-O-2 codes: C18.0-C18.9, C19.9, C20.9, C21.0-C21.2, C21.8) from 1960–2000 were extracted. Of the 17,416 pathologically confirmed cases of invasive colorectal cancer, we excluded 757 patients who were not from the five major ethnic groups (Caucasian, Japanese, Hawaiian, Filipino, and Chinese) and 235 patients for whom the diagnosis date was unknown, leaving a total sample of 16,424 cases for analysis.

Statistical Analyses

Data were first examined for ethnic differences by cohort across stage at diagnosis, age, sex, and cause of death using the likelihood ratio χ2 statistic. This statistic is interpreted in the same manner as the Pearson χ2, but provides greater precision. Next, the SAS procedure PHREG,[24] which performs regression analyses based on the Cox proportional hazards model, was used to conduct survival analyses. As a test of the validity of the proportional hazards assumption (that the hazard ratio does not change over time), the Cox proportional hazards regression was performed with a variable calculated as the mean deviated natural log of time. Significance of this variable would imply a violation of the proportional hazards assumption. Survival (survivor function) estimates (used for figures) were based on the fitted proportional hazards model, and can be interpreted as the estimates for the survivor functions controlling for the effects of the covariates.[25] The same analyses were conducted in each of three separate cohorts determined by the year of diagnosis: 1960–1974, 1975–1987, and 1988–2000. The years for the first cohort were chosen to be consistent with the study conducted by Wegner et al.[17]

The starting year for the third cohort was chosen as 1988 because that was the first year in which TNM staging data (tumor size, node status, and metastases) became available in the HTR.[26] With TNM stage data, a comparison between the predictive value of this more comprehensive form of staging (0, I, IIA, IIB, IIIA, IIIB, and IV) and the SEER staging (local, regional, distant) could be made.[26] The was accomplished by computing the increment in model fit after the TNM stage variable had been added to model containing the SEER stage variable. The likelihood ratio statistic provides this information and is distributed as chi-square, allowing for determination of statistical significance. The years for the second cohort consisted simply of the years between cohorts one and three.

Within each cohort two sets of survival analyses were performed: In the first, an event was considered to have occurred if a patient died as a result of colorectal cancer; in the second, death by any other cause was considered an event. This allowed for an assessment of whether or not changing colorectal cancer survival trends were consistent with general survival trends. Censored values included patients alive at the last data collection and patients lost to follow-up. In all analyses the effect of ethnicity on survival, while controlling for the variables stage at diagnosis (local, regional, distant), age, sex, and year of diagnosis (to control for any linear time trends existing within cohorts), was assessed using a hierarchical approach in which a model including ethnicity was compared to one that did not. Age and year of diagnosis were treated as continuous variables, as examinations did not reveal any nonlinear associations.

Results

Tables 1 and 2 provide frequency and percentage distribution data for stage at diagnosis, age, sex, and cause of death by ethnicity and cohort. The average ages for each stage at diagnosis were 66.6 years for local, 65.9 years for regional, and 65.5 years for distant. For each variable, significant ethnic differences were observed. When compared to the other ethnic groups, Hawaiians in all three cohorts were diagnosed at a more advanced stage [Likelihood Ratio χ2 (8) = 36.8, 25.0, and 46.0; p < .0001, p < .01, and p < .0001 respectively] and were more likely to have died from colorectal cancer (as opposed to death by other causes or still alive) [Likelihood Ratio χ2 (8) = 36.5, 71.2, and 69.6; p < .0001 for all]. Hawaiians also were significantly younger within cohorts 2 and 3 [Likelihood Ratio χ2 (4) = 92.3 and 180.5; p < .0001 for both]. When compared to the other ethnic groups, Filipinos had a significantly higher proportion of males in all three cohorts [Likelihood Ratio χ2 (4) = 140.1, 92.7, and 32.1; p < .0001 for all].
Table 1

Frequency of Colorectal Cancer Cases Diagnosed in Hawaii from 1960–2000.

ETHNICITY

Caucasian

Japanese

Hawaiian

Filipino

Chinese

TOTAL

COHORT

1

2

3

1

2

3

1

2

3

1

2

3

1

2

3

1

2

3

STAGE

                  

   local

318

588

994

403

901

1668

59

178

299

90

246

440

79

171

299

949

2084

3700

   regional

338

671

712

500

945

1210

57

143

279

116

236

334

97

167

191

1108

2162

2726

   distant

240

324

360

208

390

453

58

102

153

83

139

146

59

86

69

648

1041

1181

   missing

78

122

168

62

68

106

11

14

37

12

34

60

11

20

22

174

258

393

AGE

                  

   < 65

545

649

804

600

1033

1026

107

256

417

153

227

359

121

153

154

1526

2318

2760

   ≥ 65

429

1056

1430

573

1271

2411

78

181

351

148

428

621

125

291

427

1353

3227

5240

SEX

                  

   male

488

935

1299

669

1392

1985

99

266

427

259

495

637

153

248

299

1668

3336

4647

   female

486

770

935

504

912

1452

86

171

341

42

160

343

93

196

282

1211

2209

3353

DEATH

                  

   cr cancer

331

567

506

422

859

775

93

182

246

142

251

234

99

161

124

1087

2020

1885

   other

537

810

636

607

839

764

82

167

156

129

284

248

122

196

127

1477

2296

1931

   censored

106

328

1092

144

606

1898

10

88

366

30

120

498

25

87

330

315

1229

4184

TOTAL

974

1705

2234

1173

2304

3437

185

437

768

301

655

980

246

444

581

2879

5545

8000

Notes. Cohort relates years of diagnosis, where cohort 1 is 1960–1974, cohort 2 is 1975–1987, and cohort 3 is 1988–2000. Death relates cause of death information, where cr cancer indicates colorectal cancer, other indicates any other cause, and censored indicates alive or missing. Stage is SEER staging.

Table 2

Percentages of Colorectal Cancer Cases Diagnosed in Hawaii from 1960–2000.

ETHNICITY

Caucasian

Japanese

Hawaiian

Filipino

Chinese

TOTAL

COHORT

1

2

3

1

2

3

1

2

3

1

2

3

1

2

3

1

2

3

STAGE

                  

   local

32.6

34.5

44.5

34.4

39.1

48.5

31.9

40.7

38.9

29.9

37.6

44.9

32.1

38.5

51.5

33.0

37.6

46.3

   regional

34.7

39.4

31.9

42.6

41.0

35.2

30.8

32.7

36.3

38.5

36.0

34.1

39.4

37.6

32.9

38.5

39.0

34.1

   distant

24.6

19.0

16.1

17.7

16.9

13.2

31.4

23.3

19.9

27.6

21.2

14.9

24.0

19.4

11.9

22.5

18.8

14.8

   missing

8.0

7.2

7.5

5.3

3.0

3.1

5.9

3.2

4.8

4.0

5.2

6.1

4.5

4.5

3.8

6.0

4.7

4.9

AGE

                  

   < 65

56.0

38.1

36.0

51.2

44.8

29.9

57.8

58.6

54.3

50.8

34.7

36.6

49.2

34.5

26.5

53.0

41.8

34.5

   ≥ 65

44.0

61.9

64.0

48.8

55.2

70.1

42.2

41.4

45.7

49.2

65.3

63.4

50.8

65.5

73.5

47.0

58.2

65.5

SEX

                  

   male

50.1

54.8

58.1

57.0

60.4

57.8

53.5

60.9

55.6

86.0

75.6

65.0

62.2

55.9

51.5

57.9

60.2

58.1

   female

49.9

45.2

41.9

43.0

39.6

42.2

46.5

39.1

44.4

14.0

24.4

35.0

37.8

44.1

48.5

42.1

39.8

41.9

DEATH

                  

   cr cancer

34.0

33.3

22.6

36.0

37.3

22.5

50.3

41.6

32.0

47.2

38.3

23.9

40.2

36.3

21.3

37.8

36.4

23.6

   other

55.1

47.5

28.5

51.7

36.4

22.2

44.3

38.2

20.3

42.9

43.4

25.3

49.6

44.1

21.9

51.3

41.4

24.1

   censored

10.9

19.2

48.9

12.3

26.3

55.2

5.4

20.1

47.7

10.0

18.3

50.8

10.2

19.6

56.8

10.9

22.2

52.3

TOTAL

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

Notes. Cohort relates years of diagnosis, where cohort 1 is 1960–1974, cohort 2 is 1975–1987, and cohort 3 is 1988–2000. Death relates cause of death information, where cr cancer indicates colorectal cancer, other indicates any other cause, and censored indicates alive or missing. Stage is SEER staging.

Figure 1 presents the survivor function plots (stratified by ethnicity) for each cohort and for each cause of death category (controlled for stage at diagnosis, year of diagnosis, age, and sex). The corresponding five-year survivor estimates with 95% confidence intervals are shown in Table 3, and the parameter estimates for each Cox regression model are provided in Table 4. Unadjusted five-year survival rates for each ethnic group were 80.5% for Japanese, 79.4% for Caucasian, 78.8% for Chinese, 76.4% for Filipino, and 72.5% for Hawaiian. The test of the validity of the proportional hazards assumption with the variable [log e (time)-0.52] indicated no violation [χ2 (1) = 0.13, p = 0.72].
Figure 1

Estimated Survival versus Time (Years) by Ethnicity. Estimated survival (survivor functions) versus time (years) stratified by ethnicity for each cohort (1960–1974, 1975–1987, and 1988–2000) and cause of death category, controlling for the effects of SEER stage at diagnosis, year of diagnosis, age, and sex are provided.

Table 3

Probabilities of Surviving Five Years Among Three Cohorts of Colorectal Cancer Patients

COHORT

ETHNICITY

CAUSE OF DEATH

  

Colorectal Cancer

Other

1 1960–1974

Japanese

.68 (.65 – .71)

.79 (.77 – .82)

 

Caucasian

.68 (.64 – .71)

.71 (.67 – .74)

 

Chinese

.61 (.54 – .69)

.76 (.71 – .83)

 

Filipino

.47 (.41 – .55)

.69 (.62 – .76)

 

Hawaiian

.48 (.39 – .59)

.67 (.58 – .76)

2 1975–1987

Japanese

.70 (.68 – .72)

.86 (.84 – .88)

 

Caucasian

.74 (.72 – .77)

.77 (.75 – .80)

 

Chinese

.73 (.69 – .78)

.84 (.81 – .88)

 

Filipino

.66 (.62 – .70)

.77 (.74 – .81)

 

Hawaiian

.67 (.62 – .72)

.83 (.80 – .87)

3 1988–2000

Japanese

.82 (.81 – .84)

.81 (.79 – .83)

 

Caucasian

.82 (.80 – .84)

.75 (.73 – .78)

 

Chinese

.82 (.79 – .86)

.79 (.75 – .83)

 

Filipino

.81 (.78 – .84)

.76 (.72 – .80)

 

Hawaiian

.73 (.69 – .77)

.79 (.75 – .83)

Notes. Probabilities (with 95% confidence intervals) of surviving five years among three cohorts of colorectal cancer patients by ethnicity and cause of death are provided. Values reflect the estimates controlling for the effects of SEER stage at diagnosis, year of diagnosis, age, and sex.

Table 4

Determinants for Five-year Survival Among Three Cohorts of Colorectal Cancer Patients.

COHORT

VARIABLE

DEATH BY COLORECTAL CANCER

DEATH BY OTHER CAUSES

  

β

s.e.

χ2(1)

e β

β

s.e.

χ2(1)

e β

1 1960–1974

Stage

1.28

.050

659.0*

3.61

0.35

.044

65.5*

1.42

 

Year

-0.43

.071

36.6*

0.65

-0.04

.071

0.3

0.96

 

Age

0.18

.025

50.4*

1.20

0.56

.025

521.2*

1.75

 

Sex

-0.08

.066

1.5

0.92

-0.28

.056

25.6*

0.75

2 1975–1987

Stage

1.66

.037

2029.3*

5.25

0.29

.036

68.8*

1.34

 

Year

-0.14

.064

4.8

0.87

0.05

.061

0.7

1.05

 

Age

0.16

.020

64.2*

1.17

0.70

.022

997.9*

2.01

 

Sex

-0.13

.047

7.4

0.88

-0.35

.045

61.3*

0.71

3 1988–2000

Stage

1.80

.037

2398.7*

6.07

0.37

.036

102.1*

1.44

 

Year

-0.01

.052

0.1

0.99

0.37

.079

22.0*

1.45

 

Age

0.16

.021

58.6*

1.17

0.58

.023

616.2*

1.79

 

Sex

-0.10

.048

4.7

0.90

-0.29

.048

37.5*

0.75

Notes. Determinants for five-year survival among three cohorts of colorectal cancer patients by cause of death are provided. All values were obtained using the method of partial maximum likelihood estimation in Cox regression. β is the regression coefficient, and is equivalent to the log of the hazard ratio. s.e. is the standard error of the regression coefficient and is used for calculating chi-square, which in turn is used for determining the statistical significance of β. χ2(1) is the chi-square value with one degree of freedom (each variable provides a single degree of freedom) and is calculated as (β/s.e.)2. e β is the hazard ratio and is interpreted in the standard fashion. For Year (of diagnosis) and Age, the parameters reflect the estimated change per 10-year increment. Sex is coded with male as the control. An asterisk indicates significance at the .0001 level; none of the others was significant within the experimentwise α-level set to .005.

When an event was considered death by colorectal cancer, significant ethnic differences were found for all three cohorts [Likelihood Ratio χ2 (4) = 20.0, 23.1, and 12.0; p < .001, p < .001, and p < .05 respectively]. An examination of the confidence intervals for cohort 1 indicated that Japanese and Caucasian patients had significantly longer five-year survival than Filipino and Hawaiian patients. For the second cohort, the confidence intervals indicated that Caucasians had a significantly longer survival time than Filipinos; and in the third cohort, Hawaiians had significantly shorter survival time than all other ethnic groups. When an event was considered any death not caused by colorectal cancer, significant ethnic differences were again found for all three cohorts [Likelihood Ratio χ2 (4) = 46.3, 73.3, and 57.9; p < .0001 for all]. Confidence intervals indicated that the Japanese always had a significantly higher survival rate than at least one other ethnic group.

Results were largely consistent with our hypothesis, but with one major exception: the persistently low Hawaiian colorectal cancer survival in cohort 3. This unpredicted finding led to post hoc analyses that were identical to the previous Cox regression models, but included the available treatment variables (surgery, chemotherapy, radiation, and hormone therapy) as additional predictors. Table 5 provides the percentages of each ethnic group receiving a given treatment by stage. With the inclusion of treatment variables, ethnic differences were no longer significant in the third cohort, but remained significant in the first two [Likelihood Ratio χ2 (4) = 25.3, 29.1, and 8.2; p < .0001, p < .0001, and p = .08 respectively]. See Figure 2.
Figure 2

Estimated Survival versus Time (Years) by Ethnicity. Estimated survival (survivor functions) versus survival time (years) stratified by ethnicity for the third cohort (1988–2000) controlling for the effects of SEER stage at diagnosis, year of diagnosis, age, sex, and treatment are provided.

Table 5

Frequencies and Percentages of Treatments by SEER Stage and Ethnic Group for Cohort 3 (1988–2000).

STAGE

ETHNICITY

TREATMENT

  

Surgery

Chemo

Radiation

Hormone

  

N

%

N

%

N

%

N

%

Local

Japanese

1613

96.9

98

5.9

49

2.9

0

0.0

 

Caucasian

947

95.5

90

9.1

58

5.9

4

0.4

 

Chinese

293

98.3

7

2.3

5

1.7

0

0.0

 

Filipino

425

96.6

29

6.6

25

5.7

1

0.2

 

Hawaiian

290

97.3

32

10.7

23

7.7

1

0.3

Regional

Japanese

1190

98.4

581

49.2

173

14.4

11

0.9

 

Caucasian

685

96.3

281

40.7

123

17.4

3

0.4

 

Chinese

188

98.4

88

47.1

30

15.8

1

0.5

 

Filipino

326

98.2

124

37.6

56

16.9

0

0.0

 

Hawaiian

265

95.0

149

54.4

66

23.8

3

1.1

Distant

Japanese

314

69.5

240

54.3

53

11.8

2

0.4

 

Caucasian

251

69.9

126

36.2

31

8.7

4

1.1

 

Chinese

42

60.9

34

50.8

10

14.5

1

1.5

 

Filipino

103

70.6

79

55.2

21

14.5

2

1.4

 

Hawaiian

107

70.4

86

57.7

32

21.1

2

1.3

Additionally, we tested the post hoc hypothesis that Hawaiians have lower survival because they were both younger and diagnosed at a more advanced stage than the other groups. If advanced disease is more aggressive in young people, this could explain why the Hawaiians had lower survival. An interaction term between age and stage at diagnosis was created and added to the models run previously. However this interaction term did not show statistical significance, failing to support the post hoc hypothesis.

At least for cohort 3, our data also allowed us to compare the predictive value of the SEER staging variable (local, region, and distant) with that of the more comprehensive TNM staging variable. TNM staging provided significantly improved predictive value over SEER staging [Likelihood Ratio χ2 (1) = 126.4; p < .0001]. However, inclusion of TNM staging did not eliminate the Hawaiian ethnic disparity in outcome [Likelihood Ratio χ2 (4) = 11.7, p < .05], again suggesting that stage at diagnosis alone does not account for the persistently low survival among Hawaiians.

Discussion

With few exceptions, results clearly supported the stated hypothesis that ethnic disparities in colorectal cancer survival have been diminishing over time. Figure 1, showing the convergence of survival over time, best exemplifies this. The one discrepancy in this overall trend is the unchanged life expectancy for the Hawaiian group in cohort 3. A comparison with the survival curves for other causes of death within cohort 3 reveals that this effect is specific to colorectal cancer and does not reflect a general tendency for Hawaiians to die sooner.

One possible explanation for this is that Hawaiians were not utilizing medical care to treat colorectal cancer to the same degree as other ethnic groups. Our post hoc analyses did demonstrate that ethnic disparities were no longer statistically significant after controlling for treatment differences. Interestingly, however, Hawaiians did not appear to be receiving less treatment; and with respect to chemotherapy and radiation, appear to have been receiving more than the other ethnic groups. One possible explanation for this is that treatment is causing adverse effects and death. Another is that doctors see prognostic signs of severe disease that are not measured by our covariates, and therefore prescribe more treatment. That is, Hawaiians may have more advanced disease than staging alone indicates.

The implications of these findings are important. If differential screening constitutes the primary reason for ethnic survival disparities, it should be possible to achieve equally favorable outcomes in all ethnic groups. With the exception of the Hawaiians, the evidence presented here reflects a convergence in terms of screening, medical care, and colorectal cancer survival among all ethnic groups. Further efforts are needed to examine why Hawaiians do not follow the overall trend, and how to make improvements. In this regard, a Native Hawaiian cancer network called the Imi Hale is attempting, along with support from the National Cancer Institute, to increase screening for colorectal cancer in Native Hawaiians.[27]

One limitation of this study is that data are restricted to the state of Hawaii. However, even though there are clearly potential regional differences in ethnic patterns of survival, the results of this study could be important beyond Hawaii. For example, in national studies, it has been shown that African-Americans are less likely than others to receive adjuvant chemotherapy.[28] Differential treatment utilization may drive ethnic outcome disparities. The role of individual patient choice and the role of complicating co-morbid conditions in treatment selection probably play some role, and another limitation of our study is not having access to this information. In future studies, however, we hope to elucidate the impact of such factors.

To this end, an important area for future research is detailed analysis of specific treatments received by cancer patients. For example, beginning in 1988 (the start of the third cohort in the present study) colorectal cancer survival has been improved through the use of 5-fluorouracil-leucovorin as adjuvant chemotherapy.[29] This factor, as well as improving stage distribution through screening, has undoubtedly contributed to the greatly improved colorectal cancer survival rates in the third cohort. Unfortunately, the HTR does not provide adequate detail with respect to specific chemotherapy treatments, so this hypothesis could not be examined here. However, future studies incorporating expanded data sources should examine whether Hawaiians have been receiving adjuvant 5-FU-leucovorin to the same degree as others, and if not, why not (e.g., access, informed choice with refusal of recommended treatment, or co-morbid disease).

Conversely, if Hawaiians receive apparently similar adjuvant therapy (i.e., same agents, dosage, number of courses, etc.), do they benefit to the same degree as others? Also, do they show a similar degree of treatment compliance? These issues may be of particular relevance, because results from this study suggest that Hawaiians are equally likely, if not more likely, to receive treatments.

Hawaiians have been reported to have relatively high rates of diabetes, renal and vascular disease, and tend to be afflicted at a younger age. Perhaps an interaction between cancer treatment and comorbid conditions is having a negative effect on Hawaiians. We speculate that co-morbid illness might play a role in treatment selection for some individuals with colorectal cancer. Collection of ICD-9 diagnosis codes from non-HRT sources with appropriate record linkage would allow us to study this.

Other results from this study indicate that age at diagnosis is another significant predictor of survival, with older individuals having a shorter life expectancy after diagnosis. However, a comparison of hazard ratios by cause of death showed that the values were much lower for death due to colorectal cancer than for other causes. This suggests that, while age is clearly related to overall survival, it is less relevant to colorectal cancer survival. That is, colon cancer is not more deadly for older individuals than for younger ones. Similarly, sex appears to predict colorectal cancer survival. A small beneficial effect was observed for women when considering death due to colorectal cancer, but a strong effect when considering death due to other causes. The impact of co-morbid disease on survival might explain these age and gender differentials.

Stage at diagnosis represents the most important prognostic variable. In this study the SEER staging system was used so that identical analyses could be performed across all three cohorts. However, for the most recent cohort (cohort 3), TNM staging clearly improved survival predictions over the less comprehensive SEER staging. In future studies, we will use TNM staging whenever possible.

Conclusions

This study provided longitudinal evidence in support of non-biologic explanations for ethnic disparities in colorectal cancer survival. Specifically, the present analysis suggests that observed ethnic differences result from differential screening. In Hawaii, ethnic disparities in colorectal cancer survival have narrowed considerably over the past 30 years. However, Hawaiian patients did not experience the same degree of improvement in survival as the other ethnic groups.

Declarations

Acknowledgements

The help of the staff of the Hawaii Tumor Registry is greatly appreciated. This research was supported by a special study grant from the National Cancer Institute, Surveillance, Epidemiology, and End Results program under contract number N01-PC67001.

Authors’ Affiliations

(1)
Cancer Research Center of Hawai'i, University of Hawai'i
(2)
Department of Surgery, University of Hawai'i
(3)
VA Northern California Health Care System

References

  1. Ries LA, Wingo PA, Miller DS, Howe HL, Weir HK, Rosenberg HM, Vernon SW, Cronin K, Edwards BK: The annual report to the nation on the status of cancer, 1973–1997, with a special section on colorectal cancer. Cancer. 2000, 88: 2398-424. 10.1002/(SICI)1097-0142(20000515)88:10<2398::AID-CNCR26>3.0.CO;2-I.View ArticlePubMedGoogle Scholar
  2. Howe HL, Wingo PA, Thun MJ, Ries LA, Rosenberg HM, Feigal EG, Edwards BK: Annual report to the nation on the status of cancer (1973 through 1998), featuring cancers with recent increasing trends. J Natl Cancer Inst. 2001, 93: 824-42. 10.1093/jnci/93.11.824.View ArticlePubMedGoogle Scholar
  3. Piffath TA, Whiteman MK, Flaws JA, Fix AD, Busht TL: Ethnic differences in cancer mortality trends in the US, 1950–1992. Ethn Health. 2001, 6: 105-19. 10.1080/13557850120068432.View ArticlePubMedGoogle Scholar
  4. Recent trends in mortality rates for four major cancers, by sex and race/ethnicity – United States, 1990–1998. MMWR Morb Mortal Wkly Rep. 2002, 51: 49-53.Google Scholar
  5. Lin SS, Clarke CA, Prehn AW, Glaser SL, West DW, O'Malley CD: Survival differences among Asian subpopulations in the United States after prostate, colorectal, breast, and cervical carcinomas. Cancer. 2002, 94: 1175-82. 10.1002/cncr.10319.abs.View ArticlePubMedGoogle Scholar
  6. Shavers VL, Brown ML: Racial and ethnic disparities in the receipt of cancer treatment. J Natl Cancer Inst. 2002, 94: 334-57. 10.1093/jnci/94.5.334.View ArticlePubMedGoogle Scholar
  7. Cooper GS, Yuan Z, Rimm AA: Racial disparity in the incidence and case-fatality of colorectal cancer: analysis of 329 United States counties. Cancer Epidemiol Biomarkers Prev. 1997, 6: 283-5.PubMedGoogle Scholar
  8. Wudel LJ, Chapman WC, Shyr Y, Davidson M, Jeyakumar A, Rogers SO, Allos T, Stain SC: Disparate Outcomes in Patients With Colorectal Cancer: Effect of Race on Long-term Survival. Arch Surg. 2002, 137: 550-6. 10.1001/archsurg.137.5.550.View ArticlePubMedGoogle Scholar
  9. Neuhausen SL: Ethnic differences in cancer risk resulting from genetic variation. Cancer. 1999, 86: 2575-82. 10.1002/(SICI)1097-0142(19991201)86:11+<2575::AID-CNCR15>3.3.CO;2-6.View ArticlePubMedGoogle Scholar
  10. Roetzheim RG, Pal N, Gonzalez EC, Ferrante JM, Van Durme DJ, Krischer JP: Effects of health insurance and race on colorectal cancer treatments and outcomes. Am J Public Health. 2000, 90: 1746-54.View ArticlePubMedPubMed CentralGoogle Scholar
  11. Cooper GS, Yuan Z, Landefeld CS, Rimm AA: Surgery for colorectal cancer: Race-related differences in rates and survival among Medicare beneficiaries. Am J Public Health. 1996, 86: 582-6.View ArticlePubMedPubMed CentralGoogle Scholar
  12. Wojcik BE, Spinks MK, Optenberg SA: Breast carcinoma survival analysis for African American and white women in an equal-access health care system. Cancer. 1998, 82: 1310-8. 10.1002/(SICI)1097-0142(19980401)82:7<1310::AID-CNCR14>3.0.CO;2-9.View ArticlePubMedGoogle Scholar
  13. Schrijvers CT, Coebergh JW, Mackenbach JP: Socioeconomic status and comorbidity among newly diagnosed cancer patients. Cancer. 1997, 80: 1482-8. 10.1002/(SICI)1097-0142(19971015)80:8<1482::AID-CNCR16>3.3.CO;2-F.View ArticlePubMedGoogle Scholar
  14. Marcella S, Miller JE: Racial differences in colorectal cancer mortality. The importance of stage and socioeconomic status. J Clin Epidemiol. 2001, 54: 359-66. 10.1016/S0895-4356(00)00316-4.View ArticlePubMedGoogle Scholar
  15. Nomura A, Hirohata T, Rellahan W, Burch T, Harris D, Batten G: Survivorship from large bowel cancer among Caucasians and Japanese in Hawaii. Cancer. 1978, 41: 1571-6.View ArticlePubMedGoogle Scholar
  16. Hirohata T, Nomura A, Rellahan W, Burch T, Harris D, Batten G: Survival patterns from large bowel cancer in Hawaii. Hawaii Med J. 1977, 36: 343-7.PubMedGoogle Scholar
  17. Wegner EL, Kolonel LN, Nomura AM, Lee J: Racial and socioeconomic status differences in survival of colorectal cancer patients in Hawaii. Cancer. 1982, 49: 2208-16.View ArticlePubMedGoogle Scholar
  18. Hinds MW, Nomura AM, Kolonel LN, Lee J: A comparison of cancer survival by time period of diagnosis in Hawaii, 1960–1974. Cancer. 1983, 51: 175-8.View ArticlePubMedGoogle Scholar
  19. Maskarinec G, Meng L: Trends in cancer survival among different ethnic groups. Cancer Strategy. 1999, 1: 175-182.Google Scholar
  20. Maskarinec G, Pagano IS, Yamashiro G, Issell BF: Influences of ethnicity, treatment, and comorbidity on breast cancer survival in Hawaii. Journal of Clinical Epidemiology. 2002Google Scholar
  21. Hawaii Department of Business: State of Hawaii data book 1997: A statistical abstract. Honolulu: State of Hawaii. 1998Google Scholar
  22. Goodman MT, Yoshizawa CN, Kolonel LN: Descriptive epidemiology of thyroid cancer in Hawaii. Cancer. 1988, 61: 1272-81.View ArticlePubMedGoogle Scholar
  23. National Cancer Institute: SEER Program Code Manual. 1988, 3Google Scholar
  24. Sas Institute: SAS/STAT User's Guide, Version 8. Cary, NC: SAS Institute Inc. 1999Google Scholar
  25. Allison PD: Survival Analysis Using the SAS System: A Practical Guide. Cary, NC: SAS Institute. 1995Google Scholar
  26. National Cancer Institute: SEER Extent of Disease Codes and Coding Instructions. 1998, 3Google Scholar
  27. Chong C: Imi Hale, the Native Hawaiian Cancer Research and Training Network. National Cancer Institute. 2000Google Scholar
  28. Potosky AL, Harlan LC, Kaplan RS, Johnson KA, Lynch CF: Age, sex, and racial differences in the use of standard adjuvant therapy for colorectal cancer. J Clin Oncol. 2002, 20: 1192-202. 10.1200/JCO.20.5.1192.View ArticlePubMedGoogle Scholar
  29. O'Connell MJ, Mailliard JA, Kahn MJ, Macdonald JS, Haller DG, Mayer RJ, Wieand HS: Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer. J Clin Oncol. 1997, 15: 246-50.PubMedGoogle Scholar
  30. Pre-publication history

    1. The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/3/5/prepub

Copyright

© Pagano et al; licensee BioMed Central Ltd. 2003

This article is published under license to BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL.

Advertisement